Real-time 3D echocardiography can measure mitral annular size and function as accurately as MRI, according to Egyptian researchers. They studied patients with both hypertrophic cardiomyopathy and dilated cardiomyopathy.
Real-time 3D echocardiography can measure mitral annular size and function as accurately as MRI, according to Egyptian researchers. They studied patients with both hypertrophic cardiomyopathy and dilated cardiomyopathy.
Dr. Ashraf M. Anwar and colleagues in the cardiology department at Al-Husein University Hospital of Al-Azhar University in Cairo published their research in the June 5 Journal of the American Society of Echocardiography.
They studied 30 patients with hypertrophic cardiomyopathy, 20 patients with dilated cardiomyopathy, and 30 control subjects. The researchers used real-time 3D ultrasound to measure end-systolic and end-diastolic mitral annular area, mitral annular diameter, mitral annular fractional area change, and mitral annular fractional shortening. For a subset of 50 patients, they also used MRI to measure mitral annular area and mitral annular diameter.
Ultrasound measurements of the mitral annular area, fractional shortening, and fractional area change were significantly larger in hypertrophic cardiomyopathy patients than in controls.
In dilated cardiomyopathy patients, both end-systolic and end-diastolic mitral annular area measurements were higher than in controls and in hypertrophic cardiomyopathy patients, while mitral anular fractional shortening and fractional area change were lower in dilated cardiomyopathy patients than in hypertrophic cardiomyopathy patients and controls.
The researchers also found mitral annular fractional area change correlated with left ventricular function in control subjects but not in cardiomyopathy patients.
In all cases, no significant difference between the MRI measurements and the 3D ultrasound measurements was found. The researchers concluded that echocardiography was just as accurate as MRI for assessing mitral annular measurements in cardiomyopathy patients.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Philips Launches Flash 5100 Point-of-Care Ultrasound System
June 17th 2025Offering a combination of intuitive touchscreen controls and enhanced image clarity, the portable Flash 5100 POC ultrasound platform reportedly facilitates confident and rapid assessment in emergency radiology and critical care settings.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.